HK1129381A1 - Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes - Google Patents
Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymesInfo
- Publication number
- HK1129381A1 HK1129381A1 HK09107488.5A HK09107488A HK1129381A1 HK 1129381 A1 HK1129381 A1 HK 1129381A1 HK 09107488 A HK09107488 A HK 09107488A HK 1129381 A1 HK1129381 A1 HK 1129381A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegfr2
- parp
- inhibitors
- mlk3
- enzymes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20294700P | 2000-05-09 | 2000-05-09 | |
US09/850,858 US7122679B2 (en) | 2000-05-09 | 2001-05-08 | Multicyclic compounds and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129381A1 true HK1129381A1 (en) | 2009-11-27 |
Family
ID=26898160
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103639A HK1051369A1 (en) | 2000-05-09 | 2003-05-22 | Multicyclic compounds and their use as inhibitors of parp, begfr2 and mlk3 enzymes |
HK07104126.2A HK1097841A1 (en) | 2000-05-09 | 2007-04-19 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
HK09107488.5A HK1129381A1 (en) | 2000-05-09 | 2009-08-14 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103639A HK1051369A1 (en) | 2000-05-09 | 2003-05-22 | Multicyclic compounds and their use as inhibitors of parp, begfr2 and mlk3 enzymes |
HK07104126.2A HK1097841A1 (en) | 2000-05-09 | 2007-04-19 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Country Status (28)
Country | Link |
---|---|
US (1) | US7122679B2 (xx) |
EP (3) | EP2050750B1 (xx) |
JP (1) | JP5156150B2 (xx) |
KR (1) | KR100832602B1 (xx) |
CN (2) | CN100554268C (xx) |
AT (3) | ATE411997T1 (xx) |
AU (1) | AU6132701A (xx) |
BG (1) | BG66036B1 (xx) |
BR (1) | BR0110993A (xx) |
CA (1) | CA2409758A1 (xx) |
CY (1) | CY1108722T1 (xx) |
CZ (2) | CZ305350B6 (xx) |
DE (3) | DE60143140D1 (xx) |
DK (1) | DK1754707T3 (xx) |
EA (1) | EA007868B1 (xx) |
ES (2) | ES2315789T3 (xx) |
HK (3) | HK1051369A1 (xx) |
HU (1) | HU229448B1 (xx) |
IL (1) | IL152663A0 (xx) |
MX (1) | MXPA02010977A (xx) |
NO (1) | NO324256B1 (xx) |
NZ (1) | NZ522539A (xx) |
PL (1) | PL226805B1 (xx) |
PT (1) | PT1754707E (xx) |
SK (1) | SK287591B6 (xx) |
UA (1) | UA73773C2 (xx) |
WO (1) | WO2001085686A2 (xx) |
ZA (1) | ZA200209065B (xx) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US20060276497A1 (en) * | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2002354499A1 (en) * | 2001-12-18 | 2003-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Indole derivative |
US7094798B1 (en) | 2002-04-26 | 2006-08-22 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
WO2003091255A1 (en) * | 2002-04-26 | 2003-11-06 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
JP5545690B2 (ja) | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | 癌治療のためのdna損傷修復阻害剤 |
CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
CA2564952A1 (en) | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (sarms) |
US7820668B2 (en) | 2005-01-19 | 2010-10-26 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
KR20100132087A (ko) * | 2005-09-02 | 2010-12-16 | 오츠카 세이야쿠 가부시키가이샤 | 벤즈아제핀 화합물 또는 그의 염의 제조 방법 |
ATE536349T1 (de) * | 2005-09-29 | 2011-12-15 | Abbott Lab | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
PT2086525E (pt) * | 2006-11-20 | 2010-12-09 | Cephalon Inc | Método de radiossensibilização de tumores utilizando um radiossensibilizador |
EP2167075A4 (en) * | 2007-06-08 | 2012-07-11 | Univ Massachusetts | MIXED LINEAGE KINASES AND METABOLISM DISORDER |
MX2010002749A (es) | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
CN102083314B (zh) | 2007-10-03 | 2014-04-30 | 卫材股份有限公司 | Parp抑制剂化合物、组合物以及使用方法 |
US20090149417A1 (en) * | 2007-10-19 | 2009-06-11 | Valeria Ossovskaya | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors |
US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
SG185952A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
CN101999002A (zh) * | 2008-02-04 | 2011-03-30 | 彼帕科学公司 | 诊断和治疗parp-介导的疾病的方法 |
JP2010006717A (ja) * | 2008-06-24 | 2010-01-14 | Kyorin Pharmaceut Co Ltd | ジヒドロチエノ[2,3−e]インダゾール化合物 |
MY160340A (en) | 2008-10-07 | 2017-02-28 | Astrazeneca Uk Ltd | Pharmaceutical formulation 514 |
WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
ES2572652T3 (es) | 2009-08-26 | 2016-06-01 | Cephalon, Inc. | Nuevas formas de un compuesto multicíclico |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
WO2011077502A1 (ja) * | 2009-12-21 | 2011-06-30 | 杏林製薬株式会社 | ジヒドロチエノ[2,3-e]インダゾール化合物 |
US8999985B2 (en) | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
US9771325B2 (en) | 2014-02-14 | 2017-09-26 | Council Of Scientific & Industrial Research | Tricyclic compounds and preparation thereof |
WO2015121876A1 (en) * | 2014-02-14 | 2015-08-20 | Council Of Scientific & Industrial Research | Novel tricyclic compounds and preparation thereof |
AU2015353549A1 (en) | 2014-11-26 | 2017-06-01 | Cephalon, Inc. | Crystalline forms of PARP inhibitors |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
EP3325623B3 (en) | 2015-07-23 | 2021-01-20 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
SG11201903842YA (en) | 2016-11-02 | 2019-05-30 | Immunogen Inc | Combination treatment with antibody-drug conjugates and parp inhibitors |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
EP3765613A1 (en) | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法 |
EP4079726A4 (en) | 2019-12-16 | 2024-01-24 | Korea Res Inst Chemical Tech | NEW PYRIMIDINE DERIVATIVE AND CORRESPONDING USE |
US20230348399A1 (en) | 2019-12-16 | 2023-11-02 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
KR20230155351A (ko) | 2022-05-03 | 2023-11-10 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
DE3833008A1 (de) * | 1988-09-29 | 1990-04-05 | Goedecke Ag | Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US5166204A (en) * | 1989-11-01 | 1992-11-24 | Toyama Chemical Co., Ltd. | Isoindole derivatives and salts thereof and antitumor agent comprising the same |
JP3025536B2 (ja) | 1990-12-27 | 2000-03-27 | 富山化学工業株式会社 | 新規なカルバゾール誘導体およびその塩 |
JPH06507392A (ja) | 1991-02-26 | 1994-08-25 | エイアールシー 1,インコーポレイテッド | 交感神経性の持続性疼痛の治療のための組成物および方法 |
US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
GB9319297D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
AU1911095A (en) * | 1994-02-18 | 1995-09-04 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
EP0695755B1 (en) | 1994-08-04 | 1998-10-21 | F. Hoffmann-La Roche AG | Pyrrolocarbazole |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
DE69629341T2 (de) | 1995-03-09 | 2004-06-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazolderivate |
DK0971717T3 (da) * | 1996-08-22 | 2002-03-25 | Bristol Myers Squibb Co | Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler |
WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
AU9298098A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
AU9298198A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
AU748887B2 (en) | 1998-02-12 | 2002-06-13 | Myriad Genetics, Inc. | Beta-sheet mimetics and methods relating to the use thereof |
AU758241B2 (en) | 1998-03-13 | 2003-03-20 | University Of British Columbia, The | Granulatimide derivatives for use in cancer treatment |
WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
EP1077944A1 (en) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
US6063803A (en) * | 1998-06-16 | 2000-05-16 | Ortho-Mcneil Pharmaceutical, Inc. | Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents |
TR200400635T2 (tr) * | 1998-08-26 | 2005-10-21 | Cephalon, Inc. | Çok nesilli kinaz proteinlerin modüle edilmesi |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-05-08 US US09/850,858 patent/US7122679B2/en not_active Expired - Lifetime
- 2001-05-09 ES ES05076862T patent/ES2315789T3/es not_active Expired - Lifetime
- 2001-05-09 EP EP08075834A patent/EP2050750B1/en not_active Expired - Lifetime
- 2001-05-09 CZ CZ2011-756A patent/CZ305350B6/cs not_active IP Right Cessation
- 2001-05-09 AT AT05076862T patent/ATE411997T1/de active
- 2001-05-09 PL PL363167A patent/PL226805B1/pl unknown
- 2001-05-09 KR KR1020027015062A patent/KR100832602B1/ko not_active IP Right Cessation
- 2001-05-09 AU AU6132701A patent/AU6132701A/xx active Pending
- 2001-05-09 EP EP05076862A patent/EP1754707B1/en not_active Expired - Lifetime
- 2001-05-09 JP JP2001582287A patent/JP5156150B2/ja not_active Expired - Fee Related
- 2001-05-09 CA CA002409758A patent/CA2409758A1/en not_active Abandoned
- 2001-05-09 BR BR0110993-6A patent/BR0110993A/pt active Search and Examination
- 2001-05-09 CZ CZ2002-3679A patent/CZ304911B6/cs not_active IP Right Cessation
- 2001-05-09 CN CNB018120695A patent/CN100554268C/zh not_active Expired - Fee Related
- 2001-05-09 EA EA200201183A patent/EA007868B1/ru not_active IP Right Cessation
- 2001-05-09 MX MXPA02010977A patent/MXPA02010977A/es active IP Right Grant
- 2001-05-09 DE DE60143140T patent/DE60143140D1/de not_active Expired - Lifetime
- 2001-05-09 ES ES01935215T patent/ES2256238T3/es not_active Expired - Lifetime
- 2001-05-09 DE DE60116485T patent/DE60116485T2/de not_active Expired - Lifetime
- 2001-05-09 DE DE60136305T patent/DE60136305D1/de not_active Expired - Lifetime
- 2001-05-09 AT AT01935215T patent/ATE315039T1/de active
- 2001-05-09 DK DK05076862T patent/DK1754707T3/da active
- 2001-05-09 SK SK1580-2002A patent/SK287591B6/sk not_active IP Right Cessation
- 2001-05-09 CN CN2009101354977A patent/CN101560213B/zh not_active Expired - Fee Related
- 2001-05-09 IL IL15266301A patent/IL152663A0/xx not_active IP Right Cessation
- 2001-05-09 PT PT05076862T patent/PT1754707E/pt unknown
- 2001-05-09 NZ NZ522539A patent/NZ522539A/en not_active IP Right Cessation
- 2001-05-09 WO PCT/US2001/014996 patent/WO2001085686A2/en active Application Filing
- 2001-05-09 HU HU0302385A patent/HU229448B1/hu not_active IP Right Cessation
- 2001-05-09 EP EP01935215A patent/EP1294725B1/en not_active Expired - Lifetime
- 2001-05-09 AT AT08075834T patent/ATE482215T1/de not_active IP Right Cessation
- 2001-09-05 UA UA2002129794A patent/UA73773C2/uk unknown
-
2002
- 2002-11-07 ZA ZA200209065A patent/ZA200209065B/en unknown
- 2002-11-08 NO NO20025376A patent/NO324256B1/no not_active IP Right Cessation
- 2002-12-05 BG BG107355A patent/BG66036B1/bg unknown
-
2003
- 2003-05-22 HK HK03103639A patent/HK1051369A1/xx not_active IP Right Cessation
-
2007
- 2007-04-19 HK HK07104126.2A patent/HK1097841A1/xx not_active IP Right Cessation
-
2009
- 2009-01-16 CY CY20091100056T patent/CY1108722T1/el unknown
- 2009-08-14 HK HK09107488.5A patent/HK1129381A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129381A1 (en) | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes | |
WO2007149451A3 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
PL345560A1 (en) | Benzimidazole derivatives as modulators of ige | |
WO2000038717A3 (en) | Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
PT1363910E (pt) | Metodos para o tratamento de estados patologicos associados as cinases p38 e compostos de pirrolotriazina uteis como inibidores de cinases | |
WO2005016946A3 (en) | Platinum complexes for the treatment of tumors | |
EA200870048A1 (ru) | ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
WO2005021558A3 (en) | Proteasome inhibitors and methods of using the same | |
RS51630B (en) | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS β-SECRETASE INHIBITORS (BACE) | |
NO20081349L (no) | Pyrrolopyrimidinderivater som Syk-inhibitorer | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
WO2005016859A3 (en) | Proteasome inhibitors and methods of using the same | |
WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
PT1206474E (pt) | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 | |
MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
ATE420636T1 (de) | Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen | |
ATE295724T1 (de) | Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse | |
DE60133563D1 (de) | Külen | |
NO20030762D0 (no) | Forbedret spesifisitet i behandling av sykdommer | |
PT1169054E (pt) | Produtos e metodos para tratar doencas relacionadas com ptp lar | |
UA64813C2 (uk) | Інтраназальний антисептик |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190512 |